XML 52 R40.htm IDEA: XBRL DOCUMENT
v3.23.1

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Level 3 significant unobservable inputs $ in Thousands | Mar. 31, 2023 USD ($) | Dec. 31, 2022 USD ($)
--- | --- | ---
Equity and Warrant Investments |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 91,839 |  | $ 85,966
Valuation Market Approach | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 30,445 |  | 30,086
Valuation Market Approach | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 13,711 |  | $ 12,479
Valuation Market Approach | Minimum | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] | 0.0332 |  |
Valuation Market Approach | Maximum | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] | 0.3408 |  |
Market Comparable Companies | Minimum | EBITDA Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 13.3 |  | 12.4
Market Comparable Companies | Minimum | EBITDA Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 13.3 |  | 12.4
Market Comparable Companies | Minimum | Revenue Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 0.6 |  | 0.7
Market Comparable Companies | Minimum | Revenue Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 0.3 |  | 0.6
Market Comparable Companies | Minimum | Tangible Book Value Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 1.6 |  | 1.6
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] | 0.0332 |  | 0.0811
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] |  |  | 0.0811
Market Comparable Companies | Maximum | EBITDA Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 13.3 |  | 12.4
Market Comparable Companies | Maximum | EBITDA Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 13.3 |  | 12.4
Market Comparable Companies | Maximum | Revenue Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 20.6 |  | 16.1
Market Comparable Companies | Maximum | Revenue Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 10.3 |  | 8.8
Market Comparable Companies | Maximum | Tangible Book Value Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 1.6 |  | 1.6
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] | 0.3366 |  | 0.2890
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] |  |  | 0.3270
Market Comparable Companies | Weighted Average | EBITDA Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] | 13.3 |  | 12.4
Market Comparable Companies | Weighted Average | EBITDA Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] | 13.3 |  | 12.4
Market Comparable Companies | Weighted Average | Revenue Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] | 8.6 |  | 7.4
Market Comparable Companies | Weighted Average | Revenue Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] | 3.7 |  | 3.4
Market Comparable Companies | Weighted Average | Tangible Book Value Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] | 1.6 |  | 1.6
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1],[3] | 0.2421 |  | 0.1979
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1],[3] | 0.2384 |  | 0.1897
Liquidation | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 0 |  | $ 0
Liquidation | Minimum | Revenue Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 2.2 |  | 2.1
Liquidation | Minimum | Revenue Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] |  |  | 6.2
Liquidation | Minimum | Discount for Lack of Marketability | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] | 0.8600 |  | 0.8500
Liquidation | Minimum | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] |  |  | 90.00
Liquidation | Maximum | Revenue Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] | 2.2 |  | 2.1
Liquidation | Maximum | Revenue Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2] |  |  | 6.2
Liquidation | Maximum | Discount for Lack of Marketability | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] | 0.8600 |  | 0.8500
Liquidation | Maximum | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1] |  |  | 90.00
Liquidation | Weighted Average | Revenue Multiple | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] | 2.2 |  | 2.1
Liquidation | Weighted Average | Revenue Multiple | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [2],[3] |  |  | 6.2
Liquidation | Weighted Average | Discount for Lack of Marketability | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1],[3] | 0.8600 |  | 0.8500
Liquidation | Weighted Average | Discount for Lack of Marketability | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [1],[3] |  |  | 90.00
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [4] |  |  | (0.9782)
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [4] |  |  | 0.1634
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [3],[4] |  |  | (0.0886)
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [3],[4] |  |  | (0.1669)
Market Adjusted OPM Backsolve | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 12,467 |  | $ 13,795
Market Adjusted OPM Backsolve | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 7,299 |  | $ 6,934
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [4] | (0.8577) |  | (0.9782)
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [4] | (0.7190) |  |
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [4] | 0.1232 |  | 0.6643
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [4] | 0.4442 |  |
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [3],[4] | (0.1851) |  |
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [3],[4] | (0.0824) |  |
Discounted Cash Flow | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 24,595 |  | $ 19,153
Discounted Cash Flow | Minimum | Measurement Input, Discount Rate | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [5] | 0.1964 |  | 0.1772
Discounted Cash Flow | Maximum | Measurement Input, Discount Rate | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [5] | 0.3115 |  | 0.3013
Discounted Cash Flow | Weighted Average | Measurement Input, Discount Rate | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [3],[5] | 0.2566 |  | 0.2446
Other | Equity Securities |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments | [6] | $ 3,322 |  | $ 3,513
Other | Warrant |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments | [6] |  |  | 6
Investments [Member] |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 2,968,651 |  | 2,795,444
Investments [Member] | Debt Maturing Within One Year |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 97,431 |  | 93,597
Investments [Member] | Debt Investments - Imminent Payoff |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments | [7] | 235,746 |  | 77,676
Investments [Member] | Valuation Cost Approach |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 332,001 |  | 392,168
Investments [Member] | Valuation Market Approach | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 993,806 |  | 903,427
Investments [Member] | Valuation Market Approach | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 911,752 |  | 967,108
Investments [Member] | Valuation Market Approach | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 3,108 |  | 3,006
Investments [Member] | Valuation Market Approach | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 347,961 |  | 328,393
Investments [Member] | Liquidation | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | 16,343 |  |
Investments [Member] | Liquidation | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments | [8] | 1,193 |  | 1,671
Investments [Member] | Liquidation | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 7,774 | [8] | $ 8,042
Investments [Member] | Liquidation | Minimum | Collateral Recoverability | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.2500 |  |
Investments [Member] | Liquidation | Minimum | Probability weighting of alternative outcomes | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [8] | 0.1000 |  | 0.0500
Investments [Member] | Liquidation | Minimum | Probability weighting of alternative outcomes | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [8] | 0.2000 |  | 0.2000
Investments [Member] | Liquidation | Maximum | Collateral Recoverability | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.4000 |  |
Investments [Member] | Liquidation | Maximum | Probability weighting of alternative outcomes | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [8] | 0.9000 |  | 0.8000
Investments [Member] | Liquidation | Maximum | Probability weighting of alternative outcomes | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [8] | 0.8000 |  | 0.8000
Investments [Member] | Liquidation | Weighted Average | Collateral Recoverability | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.3295 |  |
Investments [Member] | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [8],[9] | 0.7954 |  | 0.4829
Investments [Member] | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [8],[9] | 0.8000 |  | 0.8000
Investments [Member] | Valuation Income Approach | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Investments |  | $ 21,536 |  | $ 20,356
Investments [Member] | Valuation Income Approach | Minimum | Probability weighting of alternative outcomes | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.0100 |  | 0.0100
Investments [Member] | Valuation Income Approach | Maximum | Probability weighting of alternative outcomes | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.5000 |  | 0.5000
Investments [Member] | Valuation Income Approach | Weighted Average | Probability weighting of alternative outcomes | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.3524 |  | 0.3579
Investments [Member] | Market Comparable Companies | Hypothetical Market Yield | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.1469 |  |
Investments [Member] | Market Comparable Companies | Premium/(Discount) | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.0075 |  |
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.1161 |  | 0.1174
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.1225 |  | 0.1205
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  |  |  | 0.1471
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.1378 |  | 0.1368
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | (0.0150) |  | (0.0075)
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | (0.0075) |  | (0.0100)
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  |  |  | 0.0075
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | (0.0200) |  | (0.0200)
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.1951 |  | 0.1904
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.2011 |  | 0.1853
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  |  |  | 0.1471
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.1714 |  | 0.1849
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.0300 |  | 0.0175
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.0300 |  | 0.0150
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  |  |  | 0.0075
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input |  | 0.0100 |  | 0.0075
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.1455 |  | 0.1517
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.1552 |  | 0.1521
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.1469 |  | 0.1471
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.1387 |  | 0.1482
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Pharmaceuticals |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.0000 |  | 0.0001
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.0030 |  | 0.0020
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Sustainable And Renewable Technology |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | 0.0075 |  | 0.0075
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Lower Middle Market |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |  |  |
Alternative Investment, Measurement Input | [9] | (0.0044) |  | (0.0043)
[1] | Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
[2] | Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
[3] | Weighted averages are calculated based on the fair market value of each investment.
[4] | Represents the range of changes in industry valuations since the portfolio company's last external valuation event.
[5] | The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
[6] | The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.
[7] | Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.
[8] | The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.
[9] | The weighted averages are calculated based on the fair market value of each investment.

X
- Definition Value of input used to measure alternative investment. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_AlternativeInvestmentMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_EquityAndWarrantInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_MarketComparableCompaniesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEbitdaMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRevenueMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputTangibleBookValueMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_WeightedAverageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueLiquidationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueMarketAdjustedOpmBacksolveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputMarketEquityAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_DebtInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtMaturingWithinOneYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtInvestmentsImminentPayoffsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_CostApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_TechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SustainableAndRenewableTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_LowerMiddleMarketMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputCollateralRecoverabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueMarketComparableCompaniesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputHypotheticalMarketYieldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputPremiumDiscountMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |